Ultimovacs ASA: The Unmet Need and Treatment Landscape of Melanoma
|DATE:||March 28, 2022|
|TIME:||10:00 AM EDT|
About The Event
Immune checkpoint inhibitors have revolutionized the management of many cancers, including melanoma. Despite the recent advancements, many advanced metastatic melanoma patients still face a significant mortality risk, underscoring the strong need for more successful, effective melanoma therapies.
This webinar will feature a presentation from renowned expert in hematology-oncology Professor Dr. Oliver E. Bechter M.D., Ph.D. (University Hospitals Leuven) who will discuss the unmet need and current treatment landscape in melanoma today. Prof. Dr. Bechter will also discuss the potential for new therapies to generate an enhanced response for melanoma patients.
Ultimovacs’ Chief Medical Officer, Jens Bjorheim M.D., Ph.D., will give an update on the company’s lead cancer vaccine candidate UV1, an “off-the-shelf” therapeutic cancer vaccine that induces a specific T cell response against human telomerase, expressed in 85 – 90% of cancers at all stages. UV1 is investigated in a Phase II trial in malignant melanoma, INITIUM.
Prof. Dr. Bechter and Ultimovacs’ senior management will be available to answer questions at the conclusion of the call.
Ultimovacs is a leader in the development of immune-stimulatory cancer vaccines. The company has initiated five Phase II trials with UV1 as an add-on therapy in more than 650 patients at 100 clinics in 15 countries. In addition to the universal cancer vaccine UV1, the company is also developing an adjuvant vaccine technology platform in Phase I.